Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Cl ...

Please provide your email address to receive an email when new articles are posted on . Rehabilitation during hospitalization vs. usual care resulted in better exercise capacity, quality of life and ...

Please provide your email address to receive an email when new articles are posted on . Experiencing an acute COPD exacerbation raised the risk for acute cardiovascular events, such as a stroke or ...

The first multisociety guidelines on the diagnosis and management of acute pulmonary embolism feature a new classification ...

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing its lead asset, rademikibart, into what it described as a novel treatment a ...

Dupilumab significantly reduced exacerbations in adults with chronic obstructive pulmonary disease by approximately 30% compared with placebo, based on data from approximately 900 individuals. Chronic ...

Imaging and clinical characteristics reach high diagnostic efficacy when they are used to identify frequent acute exacerbations in patients with chronic obstructive pulmonary disease (COPD). A mix of ...

Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).

Reinventing pulmonary care medically improves early diagnosis and interdisciplinary management for complex patients with COPD and co-morbidities.

The American Heart Association (AHA) and the American College of Cardiology (ACC) have recently released the first guideline ...

CEO Barry Quart outlined the company’s focus on rademikibart, an IL-4 receptor alpha monoclonal antibody he described as a “next-generation DUPIXENT,” during a presentation at the Leerink Partners ...